Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium.
Ischemic heart disease leading to myocardial infarction causes irreversible cell loss and scarring and is a major cause of morbidity and mortality in humans. Significant effort in the field of cardiovascular medicine has been invested in the search for adult cardiac progenitor cells that may replace damaged muscle cells and/or contribute to new vessel formation (neovascularization) and in the identification of key factors, which may induce such progenitor cells to contribute to myocardial repair and collateral vessel growth. We recently demonstrated that the actin monomer-binding protein, thymosin beta-4 (Tbeta-4), when secreted from the myocardium provides a paracrine stimulus to the cells of the epicardium-derived cells (EPDCs) to promote their inward migration and differentiation into endothelial and smooth muscle cells to form the coronary vasculature. Translating this essential role for Tbeta-4 in coronary vessel development to the adult, we found that treatment of cultured adult explants with Tbeta-4 stimulated extensive outgrowth of epicardin-positive epicardial cells, which, as they migrated away from the explant, differentiated into procollagen type I, SMalphaA, and Flk1-positive cells indicative of fibroblasts, smooth muscle, and endothelial cells; thus releasing the adult epicardium from a quiescent state and restoring pluripotency. The ability of Tbeta-4 to promote coronary vessel development and potentially induce new vasculature in the adult is essential for cardiomyocyte survival and could contribute significantly toward the reported Tbeta4-induced cardioprotection and repair in the adult heart. Tbeta-4 is currently subject to multicenter phase 1 clinical trials for treatment of cardiovascular disease (http://www.regenerx.com), therefore, insight into the repair mechanism(s) induced by Tbeta-4 is an essential step toward harnessing therapeutic survival, migration, and repair properties of the peptide in the context of acute myocardial damage.
Smart
Nicola
N
Molecular Medicine Unit, UCL Institute of Child Health, London, WC1N 1EH, UK.
Risebro
Catherine A
CA
Melville
Athalie A D
AA
Moses
Kelvin
K
Schwartz
Robert J
RJ
Chien
Kenneth R
KR
Riley
Paul R
PR
D000818:Animals; D003327:Coronary Disease / Q000517:prevention & control; D003331:Coronary Vessels / Q000254:growth & development / Q000502:physiology*; D006321:Heart / Q000187:drug effects / Q000254:growth & development / Q000502:physiology; D051379:Mice; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D010496:Pericardium / Q000187:drug effects / Q000502:physiology*; D013947:Thymosin / Q000502:physiology*; D000099201:Thymosin beta(4)
D013947:Thymosin; D000099201:Thymosin beta(4)